Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stok Raporu

Piyasa değeri: US$2.3b

Arrowhead Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Arrowhead Pharmaceuticals kazanç ve gelirinin sırasıyla yıllık 28.2% ve 46.1% oranında artması tahmin edilirken, EPS'nin yıllık 29.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

28.2%

Kazanç büyüme oranı

29.6%

EPS büyüme oranı

Biotechs kazanç büyümesi28.3%
Gelir büyüme oranı46.1%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Good

Son güncelleme20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Oct 04
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jun 12
Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: Hoping Something Sticks

May 27

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

May 21
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

May 17

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25
Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10
Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:ARWR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
9/30/2027491-327-495-736
9/30/2026240-459-546-31112
9/30/2025151-497-444-33816
9/30/202462-535-617-47916
6/30/202420-539-533-352N/A
3/31/202435-471-470-257N/A
12/31/2023182-297-403-196N/A
9/30/2023241-205-331-154N/A
6/30/2023256-181-342-197N/A
3/31/2023273-150-353-245N/A
12/31/2022278-155-236-150N/A
9/30/2022243-176-189-136N/A
6/30/2022250-154-120-91N/A
3/31/2022263-112-75-52N/A
12/31/2021144-183124149N/A
9/30/2021138-141148171N/A
6/30/2021108-126167184N/A
3/31/202189-110165181N/A
12/31/202080-103-123-111N/A
9/30/202088-85-108-96N/A
6/30/2020124-24-89-71N/A
3/31/202013910-46-27N/A
12/31/201916453-34-19N/A
9/30/201916968161173N/A
6/30/201913746152157N/A
3/31/20199510130132N/A
12/31/201847-29134136N/A
9/30/201816-54-49-47N/A
6/30/201814-54-55-54N/A
3/31/201822-44N/A-50N/A
12/31/201731-35N/A-49N/A
9/30/201731-34N/A-24N/A
6/30/201723-46N/A-25N/A
3/31/201713-60N/A-33N/A
12/31/20164-75N/A-33N/A
9/30/20160-82N/A-64N/A
6/30/20160-84N/A-66N/A
3/31/20160-81N/A-61N/A
12/31/20150-89N/A-63N/A
9/30/20150-92N/A-66N/A
6/30/20150-90N/A-65N/A
3/31/20150-85N/A-61N/A
12/31/20140-71N/A-53N/A
9/30/20140-59N/A-35N/A
6/30/20140-50N/A-30N/A
3/31/20140-44N/A-25N/A
12/31/20130-37N/A-22N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ARWR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ARWR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ARWR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ARWR şirketinin gelirinin (yıllık 46.1% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ARWR şirketinin gelirinin (yıllık 46.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ARWR 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin